Form 8-K - Current report:
SEC Accession No. 0001213900-21-059340
Filing Date
2021-11-15
Accepted
2021-11-15 16:05:46
Documents
13
Period of Report
2021-11-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea150440-8k_immucell.htm   iXBRL 8-K 30979
2 PRESS RELEASE OF IMMUCELL CORPORATION DATED NOVEMBER 15, 2021 ea150440ex99-1_immucell.htm EX-99.1 58305
  Complete submission text file 0001213900-21-059340.txt   270330

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE iccc-20211115.xsd EX-101.SCH 3025
4 XBRL LABEL FILE iccc-20211115_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE iccc-20211115_pre.xml EX-101.PRE 22359
6 EXTRACTED XBRL INSTANCE DOCUMENT ea150440-8k_immucell_htm.xml XML 3482
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 211410339
SIC: 2835 In Vitro & In Vivo Diagnostic Substances